Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis.
Rapidly progressive T-cell lymphomas were observed in 3 of 10 rhesus monkeys several months after autologous transplantation of enriched bone marrow stem cells that had been transduced with a retroviral vector preparation containing replication-competent virus (R. E. Donahue, S. W. Kessler, D. Bodice, K. McDonagh, C. Dunbar, S. Goodman, B. Agricola, E. Byrne, M. Raffeld, R. Moen, J. Bacher, K. M. Zsebo, and A. W. Nienhuis, J. Exp. Med. 176:1124-1135, 1992). The animals with lymphoma appeared to be tolerant to retroviral antigens in that their sera lacked antibodies reactive with viral proteins and contained 10(4) to 10(5) infectious virus particles per ml. By molecular cloning and DNA sequencing, we have now demonstrated that the serum from one of the monkeys contained a replication-competent retrovirus that arose by recombination between vector and packaging encoding sequences (vector/helper [V/H] recombinant) in the producer clone used for transduction of bone marrow stem cells. Southern blot analysis demonstrated 14 or 25 copies of this genome per cell where present in two animals. The genome of a second replication-competent virus was also recovered by molecular cloning; it arose by recombination involving the genome of the V/H recombinant and endogenous murine retroviral genomes in the producer clone. Twelve copies of this amphotropic virus/mink cell focus-forming virus genome were present in tumor DNA of one animal, but it was not found in tumor DNA of the other two animals with lymphoma. Southern blot analysis of DNA from various tissues demonstrated common insertion site bands in several samples of tumor DNA from one animal, suggesting clonal origin of the lymphoma. Our data are most consistent with a pathogenic mechanism in which chronic productive retroviral infection allowed insertional mutagenesis of critical growth control genes, leading to cell transformation and clonal tumor evolution.
Vanin
E F
EF
Genetic Therapy Inc., Gaithersburg, Maryland 20878.
Kaloss
M
M
Broscius
C
C
Nienhuis
A W
AW
D000818:Animals; D001483:Base Sequence; D002472:Cell Transformation, Viral; D003001:Cloning, Molecular; D046508:Culture Techniques; D004273:DNA, Neoplasm / Q000235:genetics; D004279:DNA, Viral; D015752:Genes, env; D005822:Genetic Vectors; D016399:Lymphoma, T-Cell / Q000382:microbiology*; D008253:Macaca mulatta; D008969:Molecular Sequence Data; D011533:Proviruses / Q000235:genetics; D011995:Recombination, Genetic; D012190:Retroviridae / Q000302:isolation & purification* / Q000472:pathogenicity / Q000502:physiology; D012689:Sequence Homology, Nucleic Acid; D014161:Transduction, Genetic; D014759:Viral Envelope Proteins / Q000235:genetics; D016662:Virus Integration / Q000235:genetics; D014779:Virus Replication
D004273:DNA, Neoplasm; D004279:DNA, Viral; D014759:Viral Envelope Proteins